Spero Non Current Liabilities Total from 2010 to 2024
| SPRO Stock | USD 1.41 0.04 2.76% |
Check Spero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spero Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Spero financial statements analysis is a perfect complement when working with Spero Therapeutics Valuation or Volatility modules.
Spero |
About Spero Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Spero Therapeutics income statement, its balance sheet, and the statement of cash flows. Spero Therapeutics investors use historical funamental indicators, such as Spero Therapeutics's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Spero Therapeutics investors may use each financial statement separately, they are all related. The changes in Spero Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Spero Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Spero Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Spero Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Spero Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Spero Stock
When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:Check out the analysis of Spero Therapeutics Correlation against competitors. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.